Jupiter Neurosciences Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Public

  • Employees
  • 8

Employees

  • Stock Symbol
  • JUNS

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $1.24
  • (As of Friday Closing)

Jupiter Neurosciences General Information

Description

Jupiter Neurosciences Inc is a clinical-stage research and development company focused on developing treatments for neuroinflammation through the resveratrol platform. Its platform product, JOTROL, is an enhanced oral formulation of resveratrol, which has many potential indications. In the larger disease areas, which are targeting Parkinson's Disease. The group is presently in the process of conducting a Phase IIa clinical trial in Parkinson's Disease. The company operates through two reportable segments: premium nutritional supplements and pharmaceutical operations focused on drug candidates for CNS and rare orphan diseases. It generates the majority of its revenue from Premium Nutritional Supplements, which includes commercialization and sales of the Company's Nugevia product line.

Contact Information

Formerly Known As
Jupiter Orphan Therapeutics
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 1001 North US Highway 1
  • Suite 504
  • Palm Beach Gardens, FL 33477
  • United States
Primary Industry
Drug Discovery
Other Industries
Drug Delivery
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 1001 North US Highway 1
  • Suite 504
  • Palm Beach Gardens, FL 33477
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Jupiter Neurosciences Stock Performance

As of 20-Nov-2026, Jupiter Neurosciences’s stock price is $1.24. Its current market cap is $1.63M with 1.32M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.24 $1.46 $1.20 - $97.74 $1.63M 1.32M 876K -$22.42

Jupiter Neurosciences Financials Summary

As of 30-Sep-2026, Jupiter Neurosciences has a trailing 12-month revenue of $78.6K.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 3,444 34,571 356,575
Revenue 79 22 0 0
EBITDA (13,798) (8,579) (2,197) (4,565)
Net Income (14,135) (8,645) (2,440) (4,784)
Total Assets 1,623 5,564 6,202 149
Total Debt 451 5,319 218 2,248
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Jupiter Neurosciences Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Jupiter Neurosciences‘s full profile, request access.

Request a free trial

Jupiter Neurosciences Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Jupiter Neurosciences Inc is a clinical-stage research and development company focused on developing treatments for neur
Drug Discovery
Palm Beach Gardens, FL
8 As of 2026

New Haven, CT
 

South San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Jupiter Neurosciences Competitors (6)

One of Jupiter Neurosciences’s 6 competitors is Biohaven, a Formerly VC-backed company based in New Haven, CT.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Biohaven Formerly VC-backed New Haven, CT
Denali Therapeutics Formerly VC-backed South San Francisco, CA
Larimar Therapeutics Formerly VC-backed Bala Cynwyd, PA
Biogen Formerly VC-backed Cambridge, MA
IRulya Therapeutics Formerly VC-backed New Haven, CT
To view Jupiter Neurosciences’s complete competitors history, request access »

Jupiter Neurosciences Patents

Jupiter Neurosciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20230075521-A1 Resveratrol pharmaceutical compositions and methods of use thereof Inactive 20-Aug-2021
WO-2023023323-A1 Resveratrol pharmaceutical compositions and methods of use thereof Inactive 20-Aug-2021
US-10780056-B2 Resveratrol solubilisation product for pharmaceutical purposes Active 14-Jun-2016
US-20190307700-A1 Resveratrol solubilisation product for pharmaceutical purposes Active 14-Jun-2016 A61K9/1075

Jupiter Neurosciences Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Jupiter Neurosciences Investments (1)

Jupiter Neurosciences’s most recent deal was a Corporate Asset Purchase with PharmAla Biotech (Rights of Drug ALA-002 and Royalty in Toronto, Canada) for . The deal was made on 20-Jun-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
PharmAla Biotech (Rights of Drug ALA-002 and Royalty in Toronto, Canada) 20-Jun-2026 Corporate Asset Purchase Buildings and Property
To view Jupiter Neurosciences’s complete investments history, request access »

Jupiter Neurosciences ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

39.29 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Pharmaceuticals

Subindustry

of 354

Rank

Percentile

To view Jupiter Neurosciences’s complete esg history, request access »

Jupiter Neurosciences FAQs

  • When was Jupiter Neurosciences founded?

    Jupiter Neurosciences was founded in 2015.

  • Where is Jupiter Neurosciences headquartered?

    Jupiter Neurosciences is headquartered in Palm Beach Gardens, FL.

  • What is the size of Jupiter Neurosciences?

    Jupiter Neurosciences has 8 total employees.

  • What industry is Jupiter Neurosciences in?

    Jupiter Neurosciences’s primary industry is Drug Discovery.

  • Is Jupiter Neurosciences a private or public company?

    Jupiter Neurosciences is a Public company.

  • What is Jupiter Neurosciences’s stock symbol?

    The ticker symbol for Jupiter Neurosciences is JUNS.

  • What is the current stock price of Jupiter Neurosciences?

    As of 20-Nov-2026 the stock price of Jupiter Neurosciences is $1.24.

  • What is the current market cap of Jupiter Neurosciences?

    The current market capitalization of Jupiter Neurosciences is $1.63M.

  • What is Jupiter Neurosciences’s current revenue?

    The trailing twelve month revenue for Jupiter Neurosciences is $78.6K.

  • Who are Jupiter Neurosciences’s competitors?

    Biohaven, Denali Therapeutics, Larimar Therapeutics, Biogen, and IRulya Therapeutics are some of the 6 competitors of Jupiter Neurosciences.

  • What is Jupiter Neurosciences’s annual earnings per share (EPS)?

    Jupiter Neurosciences’s EPS for 12 months was -$22.42.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process